Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] stock went on a downward path that fall over -2.90% on Wednesday, amounting to a one-week price decrease of less than -5.15%.
Over the last 12 months, BCRX stock dropped by -1.99%. The one-year Biocryst Pharmaceuticals Inc stock forecast points to a potential upside of 54.95. The average equity rating for BCRX stock is currently 1.36, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.55 billion, with 209.91 million shares outstanding and 202.70 million shares in the current float. Compared to the average trading volume of 2.91M shares, BCRX stock reached a trading volume of 5321032 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Biocryst Pharmaceuticals Inc [BCRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $16.36 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 1.36. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Evercore ISI have made an estimate for Biocryst Pharmaceuticals Inc shares, keeping their opinion on the stock as In-line, with their previous recommendation back on October 01, 2025. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on April 29, 2025, representing the official price target for Biocryst Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $15, while Wedbush analysts kept a Outperform rating on BCRX stock.
Price to Free Cash Flow for BCRX in the course of the last twelve months was 99.81 with Quick ratio for the last quarter at 2.22.
BCRX Stock Performance Analysis:
Biocryst Pharmaceuticals Inc [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.15. With this latest performance, BCRX shares dropped by -11.10% in over the last four-week period, additionally plugging by 1.66% over the last 6 months – not to mention a drop of -1.99% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 31.57, with the RSI for the last a single of trading hit 0.23, and the three-weeks RSI is set at 0.24 for Biocryst Pharmaceuticals Inc [BCRX]. The present Moving Average for the last 50 days of trading for this stock 8.17, while it was recorded at 7.56 for the last single week of trading, and 8.50 for the last 200 days.
Insight into Biocryst Pharmaceuticals Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Biocryst Pharmaceuticals Inc [BCRX] shares currently have an operating margin of 9.72% and a Gross Margin at 96.77%. Biocryst Pharmaceuticals Inc’s Net Margin is presently recorded at -6.41%.
Biocryst Pharmaceuticals Inc (BCRX) Capital Structure & Debt Analysis
Biocryst Pharmaceuticals Inc (BCRX) Efficiency & Liquidity Metrics
Biocryst Pharmaceuticals Inc (BCRX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Biocryst Pharmaceuticals Inc. (BCRX) effectively leverages its workforce, generating an average of -$61568.97 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.25% and a Quick Ratio of 2.22%, indicating strong ability to cover short-term liabilities.
BCRX Stock EPS
With the latest financial reports released by the company, Biocryst Pharmaceuticals Inc posted -0.07/share EPS, while the average EPS was predicted by analysts to be reported at -0.08/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX.
Biocryst Pharmaceuticals Inc [BCRX] Institutonal Ownership Details
There are presently around $99.39%, or 100.58%% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 19.96 million shares, which is approximately 9.6676%. VANGUARD GROUP INC, holding 18.77 million shares of the stock with an approximate value of $$116.0 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $$77.68 million in BCRX stock with ownership which is approximately 6.0894%.
